References:
1. Matsumura, Y., et al., Clinical
characteristics of Pneumocystis pneumonia in non-HIV patients and
prognostic factors including microbiological genotypes. BMC infectious
diseases, 2011. 11 (1): p. 1-9.
2. Pagano, L., et al., Pneumocystis
carinii pneumonia in patients with malignant haematological diseases: 10
years’ experience of infection in GIMEMA centres. British journal of
haematology, 2002. 117 (2): p. 379-386.
3. Caselli, D., et al., Single-day
trimethoprim/sulfamethoxazole prophylaxis for Pneumocystis pneumonia in
children with cancer. The Journal of pediatrics, 2014. 164 (2):
p. 389-392. e1.
4. Bucaneve, G., et al., Levofloxacin
to prevent bacterial infection in patients with cancer and neutropenia.
New England Journal of Medicine, 2005. 353 (10): p. 977-987.
5. Neumann, S., et al., Primary
prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia
in patients with hematological malignancies and solid tumors. Annals of
hematology, 2013. 92 (4): p. 433-442.
6. Gigliotti, F., A. Harmsen, and T.
Wright, Characterization of transmission of Pneumocystis carinii f. sp.
muris through immunocompetent BALB/c mice. Infection and Immunity, 2003.71 (7): p. 3852-3856.
7. Morris, A. and K.A. Norris,
Colonization by Pneumocystis jirovecii and its role in disease. Clinical
microbiology reviews, 2012. 25 (2): p. 297-317.
8. Vargas, S.L., et al., Search for
primary infection by Pneumocystis carinii in a cohort of normal, healthy
infants. Clinical Infectious Diseases, 2001. 32 (6): p. 855-861.
9. Douglas, C., Fungal β (1,
3)-D-glucan synthesis. Sabouraudia, 2001. 39 (1): p. 55-66.
10. Roth, A., et al., Light and
electron microscopy study of carbohydrate antigens found in the
electron-lucent layer of Pneumocystis carinii cysts. Parasitology
research, 1997. 83 (2): p. 177-184.
11. Thomas, C.F. and A.H. Limper,
Current insights into the biology and pathogenesis of Pneumocystis
pneumonia. Nature Reviews Microbiology, 2007. 5 (4): p. 298-308.
12. Ricks, D.M., et al., Dectin
immunoadhesins and pneumocystis pneumonia. Infection and immunity, 2013.81 (9): p. 3451-3462.
13. Steele, C., et al., Alveolar
macrophage–mediated killing of Pneumocystis carinii f. sp. muris
involves molecular recognition by the dectin-1 β-glucan receptor. The
Journal of experimental medicine, 2003. 198 (11): p. 1677-1688.
14. Vassallo, R., J.E. Standing, and
A.H. Limper, Isolated Pneumocystis carinii cell wall glucan provokes
lower respiratory tract inflammatory responses. The Journal of
Immunology, 2000. 164 (7): p. 3755-3763.
15. Vassallo, R., et al., Vitronectin
and fibronectin function as glucan binding proteins augmenting
macrophage responses to Pneumocystis carinii. American Journal of
Respiratory Cell and Molecular Biology, 2001. 25 (2): p.
203-211.
16. Benfield, T.L., et al.,
Prognostic value of interleukin-8 in AIDS-associated Pneumocystis
carinii pneumonia. American journal of respiratory and critical care
medicine, 1995. 151 (4): p. 1058-1062.
17. Chen, W., E.A. Havell, and A.G.
Harmsen, Importance of endogenous tumor necrosis factor alpha and gamma
interferon in host resistance against Pneumocystis carinii infection.
Infection and immunity, 1992. 60 (4): p. 1279-1284.
18. Phair, J., et al., The risk of
Pneumocystis carinii pneumonia among men infected with human
immunodeficiency virus type 1. New England journal of medicine, 1990.322 (3): p. 161-165.
19. Shellito, J., et al., A new model
of Pneumocystis carinii infection in mice selectively depleted of helper
T lymphocytes. The Journal of clinical investigation, 1990.85 (5): p. 1686-1693.
20. Avino, L.J., S.M. Naylor, and
A.M. Roecker, Pneumocystis jirovecii pneumonia in the non–HIV-infected
population. Annals of Pharmacotherapy, 2016. 50 (8): p. 673-679.
21. Iriart, X., et al., Risk factors
of Pneumocystis pneumonia in solid organ recipients in the era of the
common use of posttransplantation prophylaxis. American journal of
transplantation, 2015. 15 (1): p. 190-199.
22. Taplitz, R.A., et al.,
Antimicrobial prophylaxis for adult patients with cancer-related
immunosuppression: ASCO and IDSA clinical practice guideline update.
Journal of Clinical Oncology, 2018. 36 (30): p. 3043-3054.
23. Yale, S.H. and A.H. Limper.
Pneumocystis carinii pneumonia in patients without acquired
immunodeficiency syndrome: associated illnesses and prior corticosteroid
therapy. in Mayo Clinic Proceedings. 1996. Elsevier.
24. Park, J.W., et al., Prophylactic
effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in
patients with rheumatic diseases exposed to prolonged high-dose
glucocorticoids. Annals of the rheumatic diseases, 2018. 77 (5):
p. 644-649.
25. Huang, Y.-C., et al., Low
absolute lymphocyte count and addition of rituximab confer high risk for
interstitial pneumonia in patients with diffuse large B-cell lymphoma.
Annals of hematology, 2011. 90 (10): p. 1145-1151.
26. Cordonnier, C., et al., Fifth
European Conference on Infections in Leukemia (ECIL-5), a joint venture
of The European Group for Blood and Marrow Transplantation (EBMT), The
European Organization for Research and Treatment of Cancer (EORTC), the
Immunocompromised Host Society (ICHS) and The European LeukemiaNet
(ELN). Pneumocystis jirovecii pneumonia: still a concern in patients
with haematological malignancies and stem cell transplant recipients. J
Antimicrob Chemother, 2016. 71 (9): p. 2379-2385.
27. Kalin, M., et al., Fatal
pneumocystis jiroveci pneumonia in ABVD-treated Hodgkin lymphoma
patients. Annals of hematology, 2010. 89 (5): p. 523-525.
28. Haeusler, G.M., et al.,
Late‐onset P neumocystis jirovecii pneumonia post–fludarabine,
cyclophosphamide and rituximab: implications for prophylaxis. European
journal of haematology, 2013. 91 (2): p. 157-163.
29. De Vos, F.Y., et al.,
Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in
oncology/hematology, 2013. 85 (3): p. 373-382.
30. Sepkowitz, K.A., Opportunistic
infections in patients with and patients without acquired
immunodeficiency syndrome. Clinical infectious diseases, 2002.34 (8): p. 1098-1107.
31. Kaplan, J.E., et al.,
Epidemiology of human immunodeficiency virus-associated opportunistic
infections in the United States in the era of highly active
antiretroviral therapy. Clinical infectious diseases, 2000.30 (Supplement_1): p. S5-S14.
32. Moher, D., et al., Preferred
reporting items for systematic reviews and meta-analyses: the PRISMA
statement. PLoS medicine, 2009. 6 (7): p. e1000097.
33. Chang, H., et al., Pneumocystis
jirovecii pneumonia in patients with acute myeloid leukaemia. Internal
medicine journal, 2018. 48 (1): p. 81-83.
34. Roux, A., et al., Pneumocystis
jirovecii pneumonia in patients with or without AIDS, France. Emerging
infectious diseases, 2014. 20 (9): p. 1490.
35. Otsuka, M., et al., Torsades de
pointes complicating pentamidine therapy of Pneumocystis carinii
pneumonia in acute myelogenous leukemia. Intern Med, 1997.36 (10): p. 705-8.
36. Ong, Y.L. and F.G. Jones, A
cluster of suspected Pneumocystis carinii Pneumonia following intensive
chemotherapy in a Belfast haematology unit. Ulster Med J, 1998.67 (2): p. 104-9.
37. Chowdhary, V., et al., Sweet’s
syndrome and Pneumocystis carinii pneumonia: two sequelae of low‐dose
cytosine arabinoside therapy in a patient with acute myeloid leukemia.
European journal of haematology, 2000. 65 (1): p. 72-73.
38. Theron, J., et al., A 21-year-old
patient with acute myeloid leukemia and bilateral pulmonary infiltrates.
Respiration, 2001. 68 (6): p. 649-57.
39. Cooley, L., et al., Consensus
guidelines for diagnosis, prophylaxis and management of P neumocystis
jirovecii pneumonia in patients with haematological and solid
malignancies, 2014. Internal medicine journal, 2014. 44 (12b):
p. 1350-1363.
40. Maertens, J., et al., 5th
European Conference on Infections in Leukaemia (ECIL-5), a joint venture
of the European Group for Blood and Marrow Transplantation (EBMT), the
European Organisation for Research and Treatment of Cancer (EORTC), the
Immunocompromised Host Society (ICHS) and the European LeukemiaNet
(ELN). ECIL guidelines for preventing Pneumocystis jirovecii pneumonia
in patients with haematological malignancies and stem cell transplant
recipients. J Antimicrob Chemother, 2016. 71 (9): p. 2397-2404.
41. Toma, A., et al., Infections in
myelodysplastic syndromes. Haematologica, 2012. 97 (10): p.
1459.
42. Roblot, F., et al., Risk factors
analysis for Pneumocystis jiroveci pneumonia (PCP) in patients with
haematological malignancies and pneumonia. Scandinavian journal of
infectious diseases, 2004. 36 (11-12): p. 848-854.
43. Obeid, K.M., et al., Risk factors
for Pneumocystis jirovecii pneumonia in patients with
lymphoproliferative disorders. Clinical Lymphoma Myeloma and Leukemia,
2012. 12 (1): p. 66-69.
44. Arad-Cohen, N., J.M. Rowe, and Y.
Shachor-Meyouhas, Pharmacological prophylaxis of infection in pediatric
acute myeloid leukemia patients. Expert opinion on pharmacotherapy,
2020. 21 (2): p. 193-205.
45. Antoine, R., B. Caroline, and V.
François, All Patients with Leukemia Are Not Equally at Risk of
Contracting Pneumocystis jirovecii Pneumonia. The American journal of
medicine, 2015. 128 (1): p. e9.
46. Lemez, P., et al., Successful
prevention of Pneumocystis carinii infection with 1,920 mg of
trimethoprim-sulfamethoxazole daily in patients with malignant
hematopoietic diseases. Vnitrni lekarstvi, 1995. 41 (10): p.
688-691.
47. Drgona, L., et al., ESCMID Study
Group for Infections in Compromised Hosts (ESGICH) Consensus Document on
the safety of targeted and biological therapies: an infectious diseases
perspective (Agents targeting lymphoid or myeloid cells surface antigens
[II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clinical
Microbiology and Infection, 2018. 24 : p. S83-S94.
48. Castaigne, S., et al., Effect of
gemtuzumab ozogamicin on survival of adult patients with de-novo acute
myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.
The Lancet, 2012. 379 (9825): p. 1508-1516.
Figure 1. Flow chart of study selection for inclusion in the
systematic review.
Table 1 . Characteristic of included studies.